title: [Osteoporosis].
abstract: Calcium supplements should be used according to the dietary intakes. Daily vitamin D supplements have beneficial on bone and extraskeletal effects. Denosumab is registered in Switzerland for the treatment of postmenopausal osteoporosis and to prevent bone loss induced by sex hormone deprivation therapies in men and women. Zoledronate has a long-term efficacy on bone resorption in postmenopausal women and prevents bone loss induced by sex hormone deprivation therapies in both sexes. Teriparatide exerts beneficial effects on maxillary bone. Odanacatib decreases bone resorption and increases bone mineral density. Cinacalcet could be used as long-term treatment in case of hyperparathyroidism. Adverse events associated with the use of bisphosphonate are still under discussion. Strontium ranelate will not be introduced in Switzerland.
authors.affiliation: Service des maladies osseuses, Département de réhabilitation et de gériatrie, HUG et Faculté de médecine, 1211 Genève 14. Brigitte.Uebelhart@hcuge.ch
authors.forename: Brigitte
authors.initials: B
authors.lastname: Uebelhart
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000008:administration & dosage; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control*; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D014807:Vitamin D